Medication Adjustments for Diabetic Patients with Impaired Renal Function

Patient Assessment and Diagnosis

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend assessing the patient's eGFR and HbA1c levels to determine the best course of treatment for diabetic patients with impaired renal function, with an eGFR of 47 mL/min/1.73m² indicating moderate renal impairment 1
Patients with Type 2 Diabetes and an HbA1c of 5.4% are considered to have well-controlled blood glucose levels, but may still be at risk for hypoglycemia when taking certain medications 1

The American Diabetes Association recommends discontinuing glipizide in patients with moderate renal impairment due to the increased risk of hypoglycemia, and instead initiating metformin and an SGLT2 inhibitor as the preferred treatment regimen 2, 3
The KDIGO guidelines recommend metformin and SGLT2 inhibitors as first-line therapy for patients with T2D and CKD with eGFR ≥30 mL/min/1.73m², due to their proven cardiovascular and renal benefits 1, 4
Metformin should be initiated at a reduced dose, with a starting dose of 250-500 mg once daily, and titrated upward slowly to a maximum of half the standard maximum dose, with monitoring of kidney function every 3-6 months 1, 5
SGLT2 inhibitors provide kidney and cardiovascular protection, and can be continued even if eGFR falls below 30 mL/min/1.73m², but require monitoring for volume depletion and hypoglycemia 1, 2, 4

The KDIGO guidelines recommend monitoring eGFR every 3-6 months, and more frequently if eGFR continues to decline, to assess the effectiveness of treatment and adjust medication as needed 1
HbA1c levels should be monitored every 3 months until stable, then every 6 months, to assess glycemic control and adjust treatment as needed 6
Patients should be educated on the symptoms and management of hypoglycemia, particularly during the transition from sulfonylurea to new regimen 2

If glycemic targets are not achieved with metformin and SGLT2i, a GLP-1 receptor agonist may be considered as the preferred third agent, due to its proven efficacy in reducing glucose levels and cardiovascular risk 3, 4
If SGLT2i is contraindicated, a GLP-1 receptor agonist may be considered as an alternative, due to its similar benefits in reducing glucose levels and cardiovascular risk 4
If metformin is not tolerated, SGLT2i should still be initiated, as it provides cardiovascular and kidney benefits independent of glucose control 2